Key signaling nodes in mammary gland development and cancer: β-catenin

Breast Cancer Research

Volumn 12, Issue 6, 2010, Pages

  Incassati, Angela ^a   Chandramouli, Anupama ^a   Eelkema, Rachel ^a   Cowin, Pamela ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; WNT PROTEIN;

BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; GENE EXPRESSION REGULATION; HUMAN; MAMMARY GLAND; NONHUMAN; PREGNANCY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; BREAST TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC MOUSE; UDDER;

ANIMALS; BETA CATENIN; BREAST NEOPLASMS; CELL ADHESION; FEMALE; GENE EXPRESSION; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; STEM CELLS; WNT PROTEINS;

EID: 79960857043     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2723     Document Type: Review

References (179)

1. Boussadia O, Kutsch S, Hierholzer A, Delmas V, Kemler R. E-cadherin is a survival factor for the lactating mouse mammary gland. Mech Dev 2002, 115:53-62. 10.1016/S0925-4773(02)00090-4, 12049767.
2. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006, 10:437-449. 10.1016/j.ccr.2006.09.013, 17097565.
3. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995, 14:6107-6115. 394735, 8557030.
4. Nagi C, Guttman M, Jaffer S, Qiao R, Keren R, Triana A, Li M, Godbold J, Bleiweiss IJ, Hazan RB. N-cadherin expression in breast cancer: correlation with an aggressive histologic variant - invasive micropapillary carcinoma. Breast Cancer Res Treat 2005, 94:225-235. 10.1007/s10549-005-7727-5, 16258702.
5. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006, 66:5487-5494. 10.1158/0008-5472.CAN-06-0100, 16707478.
6. Foubert E, De Craene B, Berx G. Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res 2010, 12:206. 10.1186/bcr2585, 20594364.
7. Kowalczyk AP, Reynolds AB. Protecting your tail: regulation of cadherin degradation by p120-catenin. Curr Opin Cell Biol 2004, 16:522-527. 10.1016/j.ceb.2004.07.001, 15363802.
8. Roura S, Miravet S, Piedra J, Garcia de Herreros A, Dunach M. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 1999, 274:36734-36740. 10.1074/jbc.274.51.36734, 10593980.
9. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000, 2:203-210. 138776, 11250711, 10.1186/bcr55.
10. Shomori K, Ochiai A, Akimoto S, Ino Y, Shudo K, Ito H, Hirohashi S. Tyrosinephosphorylation of the 12th armadillo-repeat of beta-catenin is associated with cadherin dysfunction in human cancer. Int J Oncol 2009, 35:517-524.
11. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 2006, 66:5648-5655. 10.1158/0008-5472.CAN-06-0734, 16740702.
12. Rhee J, Buchan T, Zukerberg L, Lilien J, Balsamo J. Cables links Robo-bound Abl kinase to N-cadherin-bound beta-catenin to mediate Slit-induced modulation of adhesion and transcription. Nat Cell Biol 2007, 9:883-892. 10.1038/ncb1614, 17618275.
13. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009, 106:12903-12908. 2722321, 19617568, 10.1073/pnas.0810402106.
14. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009, 106:12909-12914. 2722304, 19567831, 10.1073/pnas.0810403106.
15. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 2002, 277:22692-22698. 10.1074/jbc.M201975200, 11950845.
16. Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003, 30(5 Suppl 16):38-48. 10.1053/j.seminoncol.2003.08.006, 14613025.
17. Maher MT, Mo R, Flozak AS, Peled ON, Gottardi CJ. Beta-catenin phosphorylated at serine 45 is spatially uncoupled from beta-catenin phosphorylated in the GSK3 domain: implications for signaling. PLoS One 2010, 5:e10184. 2855705, 20419129, 10.1371/journal.pone.0010184.
18. Yamamoto M, Bharti A, Kufe D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and β-catenin in cell adhesion. J Biol Chem 1997, 272:12492-12494. 10.1074/jbc.272.19.12492, 9139698.
19. Kondo K, Kohno N, Yokoyama A, Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res 1998, 58:2014-2019.
20. Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC, Gendler SJ. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004, 23:5739-5747. 10.1038/sj.onc.1207713, 15221004.
21. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009, 136:3205-3214. 10.1242/dev.033910, 19736321.
22. McNeill H, Woodgett JR. When pathways collide: collaboration and connivance among signalling proteins in development. Nat Rev Mol Cell Biol 2010, 11:404-413. 10.1038/nrm2902, 20461097.
23. Zeng YA, Nusse R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 2010, 6:568-577. 10.1016/j.stem.2010.03.020, 20569694.
24. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 2001, 3:793-801. 10.1038/ncb0901-793, 11533658.
25. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 2001, 153:1161-1174. 2192018, 11402061, 10.1083/jcb.153.6.1161.
26. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, Wicha MS. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7:e1000121. 2683567, 19492080, 10.1371/journal.pbio.1000121.
27. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of beta-catenin by activated p53. Mol Cell Biol 2001, 21:6768-6781. 99855, 11564862, 10.1128/MCB.21.20.6768-6781.2001.
28. Matsuzawa SI, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 2001, 7:915-926. 10.1016/S1097-2765(01)00242-8, 11389839.
29. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001, 7:927-936. 10.1016/S1097-2765(01)00241-6, 11389840.
30. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, Poliak N, Califano J, Trink B, Ratovitski E, Sidransky D. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 2002, 1:369-379. 10.1016/S1535-6108(02)00057-0, 12086851.
31. Lamberti C, Lin KM, Yamamoto Y, Verma U, Verma IM, Byers S, Gaynor RB. Regulation of beta-catenin function by the IκB kinases. J Biol Chem 2001, 276:42276-42286. 10.1074/jbc.M104227200, 11527961.
32. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
33. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88. 10.1038/nature04372, 16397499.
34. Badders NM, Goel S, Clark RJ, Klos KS, Kim S, Bafico A, Lindvall C, Williams BO, Alexander CM. The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. PLoS One 2009, 4:e6594. 2720450, 19672307, 10.1371/journal.pone.0006594.
35. Cowin P, Wysolmerski J. Molecular mechanisms guiding embryonic mammary gland development. Cold Spring Harb Perspect Biol 2010, 2:a003251. 2869520, 20484386, 10.1101/cshperspect.a003251.
36. Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, Brisken C, Glick A, Wysolmerski JJ, Millar SE. Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development 2004, 131:4819-4829. 10.1242/dev.01347, 15342465.
37. van Genderen C, Okamura RM, Farinas I, Quo R-G, Parslow TG, Bruhn L, Grosschedl R. Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in Lef-1 deficient mice. Genes and Development 1994, 8:2691-2704.
38. Gu B, Sun P, Yuan Y, Moraes RC, Li A, Teng A, Agrawal A, Rheaume C, Bilanchone V, Veltmaat JM, Takemaru K, Millar S, Lee EY, Lewis MT, Li B, Dai X. Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation. J Cell Biol 2009, 185:811-826. 2711593, 19487454, 10.1083/jcb.200810133.
39. Lindvall C, Evans NC, Zylstra CR, Li Y, Alexander CM, Williams BO. The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J Biol Chem 2006, 281:35081-35087. 10.1074/jbc.M607571200, 16973609.
40. Lindvall C, Zylstra CR, Evans N, West RA, Dykema K, Furge KA, Williams BO. The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development. PLoS One 2009, 4:e5813. 2686096, 19503830, 10.1371/journal.pone.0005813.
41. Cho KW, Kim JY, Song SJ, Farrell E, Eblaghie MC, Kim HJ, Tickle C, Jung HS. Molecular interactions between Tbx3 and Bmp4 and a model for dorsoventral positioning of mammary gland development. Proc Natl Acad Sci USA 2006, 103:16788-16793. 1636533, 17071745, 10.1073/pnas.0604645103.
42. Veltmaat JM, Relaix F, Le LT, Kratochwil K, Sala FG, van Veelen W, Rice R, Spencer-Dene B, Mailleux AA, Rice DP, Thiery JP, Bellusci S. Gli3-mediated somitic Fgf10 expression gradients are required for the induction and patterning of mammary epithelium along the embryonic axes. Development 2006, 133:2325-2335. 10.1242/dev.02394, 16720875.
43. Mailleux AA, Spencer-Dene B, Dillon C, Ndiaye D, Savona-Baron C, Itoh N, Kato S, Dickson C, Thiery JP, Bellusci S. Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development 2002, 129:53-60.
44. Jerome-Majewska LA, Jenkins GP, Ernstoff E, Zindy F, Sherr CJ, Papaioannou VE. Tbx3, the ulnar-mammary syndrome gene, and Tbx2 interact in mammary gland development through a p19Arf/p53-independent pathway. Dev Dyn 2005, 234:922-933. 10.1002/dvdy.20575, 16222716.
45. Davenport TG, Jerome-Majewska LA, Papaioannou VE. Mammary gland, limb and yolk sac defects in mice lacking Tbx3, the gene mutated in human ulnar mammary syndrome. Development 2003, 130:2263-2273. 10.1242/dev.00431, 12668638.
46. Howard B, Panchal H, McCarthy A, Ashworth A. Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification. Genes Dev 2005, 19:2078-2090. 1199577, 16140987, 10.1101/gad.338505.
47. Eblaghie MC, Song SJ, Kim JY, Akita K, Tickle C, Jung HS. Interactions between FGF and Wnt signals and Tbx3 gene expression in mammary gland initiation in mouse embryos. J Anat 2004, 205:1-13. 1571327, 15255957, 10.1111/j.0021-8782.2004.00309.x.
48. Veltmaat JM, Van Veelen W, Thiery JP, Bellusci S. Identification of the mammary line in mouse by Wnt10b expression. Dev Dyn 2004, 229:349-356. 10.1002/dvdy.10441, 14745960.
49. Pummila M, Fliniaux I, Jaatinen R, James MJ, Laurikkala J, Schneider P, Thesleff I, Mikkola ML. Ectodysplasin has a dual role in ectodermal organogenesis: inhibition of Bmp activity and induction of Shh expression. Development 2007, 134:117-125. 10.1242/dev.02708, 17164417.
50. Boras-Granic K, Chang H, Grosschedl R, Hamel PA. Lef1 is required for the transition of Wnt signaling from mesenchymal to epithelial cells in the mouse embryonic mammary gland. Dev Biol 2006, 295:219-231. 10.1016/j.ydbio.2006.03.030, 16678815.
51. Abdalkhani A, Sellers R, Gent J, Wulitich H, Childress S, Stein B, Boissy RE, Wysolmerski JJ, Foley J. Nipple connective tissue and its development: insights from the K14-PTHrP mouse. Mech Dev 2002, 115:63-77. 10.1016/S0925-4773(02)00092-8, 12049768.
52. Dunbar ME, Dann PR, Robinson GW, Hennighausen L, Zhang JP, Wysolmerski JJ. Parathyroid hormone-related protein signaling is necessary for sexual dimorphism during embryonic mammary development. Development 1999, 126:3485-3493.
53. Foley J, Dann P, Hong J, Cosgrove J, Dreyer B, Rimm D, Dunbar M, Philbrick W, Wysolmerski J. Parathyroid hormone-related protein maintains mammary epithelial fate and triggers nipple skin differentiation during embryonic breast development. Development 2001, 128:513-525.
54. Hens JR, Dann P, Zhang JP, Harris S, Robinson GW, Wysolmerski J. BMP4 and PTHrP interact to stimulate ductal outgrowth during embryonic mammary development and to inhibit hair follicle induction. Development 2007, 134:1221-1230. 10.1242/dev.000182, 17301089.
55. Wysolmerski JJ, McCaughern-Carucci JF, Daifotis AG, Broadus AE, Philbrick WM. Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. Development 1995, 121:3539-3547.
56. Wysolmerski JJ, Philbrick WM, Dunbar ME, Lanske B, Kronenberg H, Broadus AE. Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development 1998, 125:1285-1294.
57. Hens J, Dann P, Hiremath M, Pan TC, Chodosh L, Wysolmerski J. Analysis of gene expression in PTHrP-/- mammary buds supports a role for BMP signaling and MMP2 in the initiation of ductal morphogenesis. Dev Dyn 2009, 238:2713-2724. 2862621, 19795511, 10.1002/dvdy.22097.
58. Bradbury JM, Edwards PA, Niemeyer CC, Dale TC. Wnt-4 expression induces a pregnancy-like growth pattern in reconstituted mammary glands in virgin mice. Dev Biol 1995, 170:553-563. 10.1006/dbio.1995.1236, 7649383.
59. Weber-Hall SJ, Phippard DJ, Niemeyer CC, Dale TC. Developmental and hormonal regulation of Wnt gene expression in the mouse mammary gland. Differentiation 1994, 57:205-214. 10.1046/j.1432-0436.1994.5730205.x, 7988795.
60. Buhler TA, Dale TC, Kieback C, Humphreys RC, Rosen JM. Localization and quantification of Wnt-2 gene expression in mouse mammary development. Dev Biol 1993, 155:87-96. 10.1006/dbio.1993.1009, 8416847.
61. Lane TF, Leder P. Wnt10B directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 1997, 15:2133-2144. 10.1038/sj.onc.1201593, 9393971.
62. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W, Behrens J. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002, 22:1184-1193. 134640, 11809809, 10.1128/MCB.22.4.1184-1193.2002.
63. Kouros-Mehr H, Werb Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn 2006, 235:3404-3412. 2730892, 17039550, 10.1002/dvdy.20978.
64. Roarty K, Serra R. Wnt5a is required for proper mammary gland development and TGF-β-mediated inhibition of ductal growth. Development 2007, 134:3929-3939. 10.1242/dev.008250, 17898001.
65. Ismail PM, Li J, DeMayo FJ, O'Malley BW, Lydon JP. A novel LacZ reporter mouse reveals complex regulation of the progesterone receptor promoter during mammary gland development. Mol Endocrinol 2002, 16:2475-2489. 10.1210/me.2002-0169, 12403837.
66. Hiremath M, Lydon JP, Cowin P. The pattern of beta-catenin responsiveness within the mammary gland is regulated by progesterone receptor. Development 2007, 134:3703-3712. 10.1242/dev.006585, 17881490.
67. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, Cowin P. MMTV-Wnt1 and -ΔN89β-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS One 2009, 4:e4537. 2639708, 19225568, 10.1371/journal.pone.0004537.
68. Brisken C, Park S, Vass T, Lydon JP, O'Malley BW, Weinberg RA. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci USA 1998, 95:5076-5081. 20216, 9560231, 10.1073/pnas.95.9.5076.
69. Brisken C, Heineman A, Chavarra T, Elenbaas B, Tan J, Dey SK, McMahon AP, Weinberg R. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 2000, 14:650-654. 316462, 10733525.
70. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi P, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010,
71. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807. 10.1038/nature09091, 20445538.
72. Kim YC, Clark RJ, Pelegri F, Alexander CM. Wnt4 is not sufficient to induce lobuloalveolar mammary development. BMC Dev Biol 2009, 9:55. 2777140, 19878558, 10.1186/1471-213X-9-55.
73. Chadi S, Buscara L, Pechoux C, Costa J, Laubier J, Chaboissier MC, Pailhoux E, Vilotte JL, Chanat E, Le Provost F. R-spondin1 is required for normal epithelial morphogenesis during mammary gland development. Biochem Biophys Res Commun 2009, 390:1040-1043. 10.1016/j.bbrc.2009.10.104, 19857464.
74. Teuliere J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, Thiery JP, Glukhova MA. Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development 2005, 132:267-277. 10.1242/dev.01583, 15590737.
75. Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P. ΔN89β-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol 2001, 153:555-568. 2190562, 11331306, 10.1083/jcb.153.3.555.
76. Hsu W, Shakya R, Costantini F. Impaired mammary gland and lymphoid development caused by inducible expression of Axin in transgenic mice. J Cell Biol 2001, 155:1055-1064. 2150907, 11739413, 10.1083/jcb.200107066.
77. Tepera SB, McCrea PD, Rosen JM. A beta-catenin survival signal is required for normal lobular development in the mammary gland. J Cell Sci 2003, 116(Pt 6):1137-1149. 10.1242/jcs.00334, 12584256.
78. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50. 10.1016/S0092-8674(00)00103-3, 11051546.
79. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 2010, 107:2989-2994. 2840294, 20133621, 10.1073/pnas.0915148107.
80. Liou YC, Ryo A, Huang HK, Lu PJ, Bronson R, Fujimori F, Uchida T, Hunter T, Lu KP. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci USA 2002, 99:1335-1340. 122191, 11805292, 10.1073/pnas.032404099.
81. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021. 10.1038/35082500, 11429595.
82. Rowlands TM, Pechenkina IV, Hatsell SJ, Pestell RG, Cowin P. Dissecting the roles of beta-catenin and cyclin D1 during mammary development and neoplasia. Proc Natl Acad Sci USA 2003, 100:11400-11405. 208769, 13679587, 10.1073/pnas.1534601100.
83. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31:99-109. 10.1016/0092-8674(82)90409-3, 6297757.
84. Tsukamoto A, Grosschedl R, Guzman R, Parslow T, Varmus H. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988, 55:619-625. 10.1016/0092-8674(88)90220-6, 3180222.
85. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands T, Egeblad M, Cowin P, Werb Z, Tan LK, Rosen JM, Varmus HE. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 2003, 100:15853-15858. 307657, 14668450, 10.1073/pnas.2136825100.
86. Liu BY, Kim YC, Leatherberry V, Cowin P, Alexander CM. Mammary gland development requires syndecan-1 to create a beta-catenin/TCF-responsive mammary epithelial subpopulation. Oncogene 2003, 22:9243-9253. 10.1038/sj.onc.1207217, 14681683.
87. Liu BY, McDermott SP, Khwaja SS, Alexander CM. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci USA 2004, 101:4158-4163. 384711, 15020770, 10.1073/pnas.0400699101.
88. Zhang J, Li Y, Liu Q, Lu W, Bu G. Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis. Oncogene 2010, 29:539-549. 2813429, 19881541, 10.1038/onc.2009.339.
89. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff RD, Chodosh LA. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 2003, 17:488-501. 195997, 12600942, 10.1101/gad.1051603.
90. Michaelson JS, Leder P. β-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 2001, 20:5093-5099. 10.1038/sj.onc.1204586, 11526497.
91. Rowlands TM, Pechenkina IV, Hatsell S, Cowin P. Beta-catenin and cyclin D1: connecting development to breast cancer. Cell Cycle 2004, 3:145-148.
92. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007, 104:618-623. 1766434, 17202265, 10.1073/pnas.0606599104.
93. Miyoshi K, Shillingford JM, Le Provost F, Gounari F, Bronson R, von Boehmer H, Taketo MM, Cardiff RD, Hennighausen L, Khazaie K. Activation of betacatenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci USA 2002, 99:219-224. 117542, 11773619, 10.1073/pnas.012414099.
94. Kuraguchi M, Ohene-Baah NY, Sonkin D, Bronson RT, Kucherlapati R. Genetic mechanisms in Apc-mediated mammary tumorigenesis. PLoS Genet 2009, 5:e1000367. 2629572, 19197353, 10.1371/journal.pgen.1000367.
95. Gaspar C, Franken P, Molenaar L, Breukel C, van der Valk M, Smits R, Fodde R. A targeted constitutive mutation in the APC tumor suppressor gene underlies mammary but not intestinal tumorigenesis. PLoS Genet 2009, 5:e1000547. 2697381, 19578404, 10.1371/journal.pgen.1000547.
96. Wang H, Teske D, Tess A, Kohlhepp R, Choi Y, Kendziorski C, Moser AR. Identification of novel modifier loci of Apc Min affecting mammary tumor development. Cancer Res 2007, 67:11226-11233. 10.1158/0008-5472.CAN-07-2487, 18056448.
97. Roarty K, Baxley SE, Crowley MR, Frost AR, Serra R. Loss of TGF-β or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res 2009, 11:R19. 2688948, 19344510, 10.1186/bcr2244.
98. Kim YC, Clark RJ, Ranheim EA, Alexander CM. Wnt1 expression induces short-range and long-range cell recruitments that modify mammary tumor development and are not induced by a cell-autonomous betacatenin effector. Cancer Res 2008, 68:10145-10153. 2827297, 19074881, 10.1158/0008-5472.CAN-08-2992.
99. Cho RW, Wang X, Diehn M, Shedden K, Chen GY, Sherlock G, Gurney A, Lewicki J, Clarke MF. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 2008, 26:364-371. 10.1634/stemcells.2007-0440, 17975224.
100. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009, 69:5364-5373. 2782448, 19549913, 10.1158/0008-5472.CAN-08-4135.
101. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010, 176:2911-2920. 10.2353/ajpath.2010.091125, 20395444.
102. Liu CC, Prior J, Piwnica-Worms D, Bu G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA 2010, 107:5136-5141. 2841938, 20194742, 10.1073/pnas.0911220107.
103. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76. 1929138, 17493263, 10.1186/gb-2007-8-5-r76.
104. Sawyer EJ, Hanby AM, Rowan AJ, Gillett CE, Thomas RE, Poulsom R, Lakhani SR, Ellis IO, Ellis P, Tomlinson IP. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol 2002, 196:437-444. 10.1002/path.1067, 11920740.
105. Abraham SC, Reynolds C, Lee JH, Montgomery EA, Baisden BL, Krasinskas AM, Wu TT. Fibromatosis of the breast and mutations involving the APC/betacatenin pathway. Hum Pathol 2002, 33:39-46. 10.1053/hupa.2002.30196, 11823972.
106. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 2008, 14:4038-4044. 10.1158/1078-0432.CCR-07-4379, 18593979.
107. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000, 97:4262-4266. 18221, 10759547, 10.1073/pnas.060025397.
108. Jonsson M, Borg A, Nilbert M, Andersson T. Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer 2000, 36:242-248. 10.1016/S0959-8049(99)00276-2, 10741284.
109. Ozaki S, Ikeda S, Ishizaki Y, Kurihara T, Tokumoto N, Iseki M, Arihiro K, Kataoka T, Okajima M, Asahara T. Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep 2005, 14:1437-1443.
110. Sormunen RT, Leong AS, Vaaraniemi JP, Fernando SS, Eskelinen SM. Immunolocalization of the fodrin, E-cadherin, and beta-catenin adhesion complex in infiltrating ductal carcinoma of the breast-comparison with an in vitro model. J Pathol 1999, 187:416-423. 10.1002/(SICI)1096-9896(199903)187:4<416::AID-PATH255>3.0.CO;2-D, 10398100.
111. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, Keramopoulos A, Davaris PS, Pignatelli M. Expression patterns of beta-catenin in in situ and invasive breast cancer. Eur J Surg Oncol 2001, 27:31-36. 10.1053/ejso.1999.1017, 11237489.
112. Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol 2002, 196:145-153. 10.1002/path.1035, 11793365.
113. Prasad CP, Gupta SD, Rath G, Ralhan R. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression. Oncology 2007, 73:112-117. 10.1159/000120999, 18337623.
114. Prasad CP, Mirza S, Sharma G, Prashad R, DattaGupta S, Rath G, Ralhan R. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci 2008, 83:318-325. 10.1016/j.lfs.2008.06.019, 18662704.
115. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A, Pilarsky C. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003, 201:204-212. 10.1002/path.1449, 14517837.
116. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F, Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, Pebusque MJ. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 2001, 20:5810-5817. 10.1038/sj.onc.1204706, 11593386.
117. Shulewitz M, Soloviev I, Wu T, Koeppen H, Polakis P, Sakanaka C. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. Oncogene 2006, 25:4361-4369. 10.1038/sj.onc.1209470, 16532032.
118. Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 2006, 27:1341-1348. 10.1093/carcin/bgi379, 16501252.
119. Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res 2009, 11:R32. 2716500, 19473496, 10.1186/bcr2317.
120. Gauger KJ, Hugh JM, Troester MA, Schneider SS. Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis. Cancer Cell Int 2009, 9:11. 2687411, 19422694, 10.1186/1475-2867-9-11.
121. Yang ZQ, Liu G, Bollig-Fischer A, Haddad R, Tarca AL, Ethier SP. Methylationassociated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers. Int J Cancer 2009, 125:1613-1621. 2735097, 19569235, 10.1002/ijc.24518.
122. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Durst M, Kristiansen G, Huszka C, Knuchel R, Dahl E. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006, 25:3479-3488. 10.1038/sj.onc.1209386, 16449975.
123. Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R, Dahl E. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis 2008, 29:991-998. 10.1093/carcin/bgn076, 18356147.
124. Veeck J, Wild PJ, Fuchs T, Schuffler PJ, Hartmann A, Knuchel R, Dahl E. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer 2009, 9:217. 2717119, 19570204, 10.1186/1471-2407-9-217.
125. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB, Tokino T. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 2008, 98:1147-1156. 2275475, 18283316, 10.1038/sj.bjc.6604259.
126. Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, Tanguay S, Lapointe R. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 2007, 96:646-653. 2360041, 17245340, 10.1038/sj.bjc.6603579.
127. Kirikoshi H, Sekihara H, Katoh M. Expression of WNT14 and WNT14B mRNAs in human cancer, up-regulation of WNT14 by IFNγ and up-regulation of WNT14B by beta-estradiol. Int J Oncol 2001, 19:1221-1225.
128. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 1994, 54:2615-2621.
129. Dale TC, Weber-Hall SJ, Smith K, Huguet EL, Jayatilake H, Gusterson BA, Shuttleworth G, O'Hare M, Harris AL. Compartment switching of Wnt-2 expression in human breast tumors. Cancer Res 1996, 56:4320-4323.
130. Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep 2006, 15:701-707.
131. Lejeune S, Huguet EL, Hamby A, Poulsom R, Harris AL. Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1995, 1:215-222.
132. Katoh M. Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. Int J Oncol 2001, 19:1003-1007.
133. Bui TD, Rankin J, Smith K, Huguet EL, Ruben S, Strachan T, Harris AL, Lindsay S. A novel human Wnt gene, WNT10B, maops to 12q13 and is expressed in human breast carcinomas. Oncogene 1997, 14:1249-1253. 10.1038/sj.onc.1200936, 9121776.
134. Watanabe O, Imamura H, Shimizu T, Kinoshita J, Okabe T, Hirano A, Yoshimatsu K, Konno S, Aiba M, Ogawa K. Expression of twist and wnt in human breast cancer. Anticancer Res 2004, 24:3851-3856.
135. Jonsson M, Dejmek J, Bendahl PO, Andersson T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 2002, 62:409-416.
136. Milovanovic T, Planutis K, Nguyen A, Marsh JL, Lin F, Hope C, Holcombe RF. Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol 2004, 25:1337-1342.
137. Bjorklund P, Svedlund J, Olsson AK, Akerstrom G, Westin G. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS One 2009, 4:e4243. 2627768, 19158955, 10.1371/journal.pone.0004243.
138. Nagahata T, Shimada T, Harada A, Nagai H, Onda M, Yokoyama S, Shiba T, Jin E, Kawanami O, Emi M. Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila disheveled gene, in primary breast cancers. Cancer Sci 2003, 94:515-518. 10.1111/j.1349-7006.2003.tb01475.x, 12824876.
139. Sorlie T, Bukholm I, Borresen-Dale AL. Truncating somatic mutation in exon 15 of the APC gene is a rare event in human breast carcinomas. Mutations in brief no. 179. Online. Hum Mutat 1998, 12:215-216.
140. Schlosshauer PW, Brown SA, Eisinger K, Yan Q, Guglielminetti ER, Parsons R, Ellenson LH, Kitajewski J. APC truncation and increased beta-catenin levels in a human breast cancer cell line. Carcinogenesis 2000, 21:1453-1456. 10.1093/carcin/21.7.1453, 10874025.
141. Furuuchi K, Tada M, Yamada H, Kataoka A, Furuuchi N, Hamada J, Takahashi M, Todo S, Moriuchi T. Somatic mutations of the APC gene in primary breast cancers. Am J Pathol 2000, 156:1997-2005. 1850076, 10854222.
142. Wang X, Goode EL, Fredericksen ZS, Vierkant RA, Pankratz VS, Liu-Mares W, Rider DN, Vachon CM, Cerhan JR, Olson JE, Couch FJ. Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:2101-2108. 2771409, 18708403, 10.1158/1055-9965.EPI-08-0134.
143. Thompson AM, Morris RG, Wallace M, Wyllie AH, Steel CM, Carter DC. Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. Br J Cancer 1993, 68:64-68. 1968317, 8318422.
144. Sarrio D, Moreno-Bueno G, Hardisson D, Sanchez-Estevez C, Guo M, Herman JG, Gamallo C, Esteller M, Palacios J. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003, 106:208-215. 10.1002/ijc.11197, 12800196.
145. Kashiwaba M, Tamura G, Ishida M. Aberrations of the APC gene in primary breast carcinoma. J Cancer Res Clin Oncol 1994, 120:727-731. 10.1007/BF01194271, 7798298.
146. Medeiros AC, Nagai MA, Neto MM, Brentani RR. Loss of heterozygosity affecting the APC and MCC genetic loci in patients with primary breast carcinomas. Cancer Epidemiol Biomarkers Prev 1994, 3:331-333.
147. Ho KY, Kalle WH, Lo TH, Lam WY, Tang CM. Reduced expression of APC and DCC gene protein in breast cancer. Histopathology 1999, 35:249-256. 10.1046/j.1365-2559.1999.00725.x, 10469217.
148. Webster MT, Rozycka M, Sara E, Davis E, Smalley M, Young N, Dale TC, Wooster R. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 2000, 28:443-453. 10.1002/1098-2264(200008)28:4<443::AID-GCC10>3.0.CO;2-D, 10862053.
149. Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M, Motoyama T. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001, 85:69-73. 2363914, 11437404, 10.1054/bjoc.2001.1853.
150. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, Farinas AJ, Milchgrub S, Euhus DM, Gilcrease M, Herman J, Minna JD, Gazdar AF. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001, 7:1998-2004.
151. Roh MS, Hong SH, Jeong JS, Kwon HC, Kim MC, Cho SH, Yoon JH, Hwang TH. Gene expression profiling of breast cancers with emphasis of beta-catenin regulation. J Korean Med Sci 2004, 19:275-282. 2822311, 15082903, 10.3346/jkms.2004.19.2.275.
152. Van der Auwera I, Van Laere SJ, Van den Bosch SM, Van den Eynden GG, Trinh BX, van Dam PA, Colpaert CG, van Engeland M, Van Marck EA, Vermeulen PB, Dirix LY. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer 2008, 99:1735-1742. 2584952, 18841156, 10.1038/sj.bjc.6604705.
153. Andrews PG, Lake BB, Popadiuk C, Kao KR. Requirement of Pygopus 2 in breast cancer. Int J Oncol 2007, 30:357-363.
154. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R, Zhang Y, Hong M, Shang Y. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007, 27:5105-5119. 1951944, 17502350, 10.1128/MCB.00162-07.
155. Aulmann S, Bentz M, Sinn HP. C-myc oncogene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2002, 74:25-31. 10.1023/A:1016061327812, 12150449.
156. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994, 54:1812-1817.
157. Musgrove EA, Hui R, Sweeney KJ, Watts CK, Sutherland RL. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 1996, 1:153-162. 10.1007/BF02013639, 10887489.
158. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, Vidaud M. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 1999, 59:2759-2765.
159. Cowling VH, D'Cruz CM, Chodosh LA, Cole MD. c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol 2007, 27:5135-5146. 1951955, 17485441, 10.1128/MCB.02282-06.
160. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev 2000, 14:585-595. 316421, 10716946.
161. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001, 61:8917-8923.
162. Fu DY, Wang ZM, Li C, Wang BL, Shen ZZ, Huang W, Shao ZM. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat 2010, 119:601-612. 10.1007/s10549-009-0339-8, 19301122.
163. Rieger ME, Sims AH, Coats ER, Clarke RB, Briegel KJ. The embryonic transcription cofactor LBH is a direct target of the WNT signaling pathway in epithelial development and in aggressive basal subtype breast cancers. Mol Cell Biol 2010, 30:4267-4279. 10.1128/MCB.01418-09, 20606007.
164. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, Lu KP. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001, 20:3459-3472. 125530, 11432833, 10.1093/emboj/20.13.3459.
165. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004, 101:10137-10142. 454178, 15220474, 10.1073/pnas.0403621101.
166. Farooq A, Walker LJ, Bowling J, Audisio RA. Cowden syndrome. Cancer Treat Rev 2010,
167. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001, 14:672-676. 10.1038/modpathol.3880371, 11454999.
168. Zhao H, Cui Y, Dupont J, Sun H, Hennighausen L, Yakar S. Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis. Cancer Res 2005, 65:6864-6873. 10.1158/0008-5472.CAN-05-0181, 16061670.
169. Lee JY, Kang MB, Jang SH, Qian T, Kim HJ, Kim CH, Kim Y, Kong G. Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition. Oncogene 2009, 28:824-831. 10.1038/onc.2008.451, 19079342.
170. Prasad A, Paruchuri V, Preet A, Latif F, Ganju RK. Slit-2 induces a tumorsuppressive effect by regulating beta-catenin in breast cancer cells. J Biol Chem 2008, 283:26624-26633. 2546548, 18611862, 10.1074/jbc.M800679200.
171. Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I, Saito Y, Hunt KK, Grimm EA, Roth JA, Meyn RE, Ramesh R, Chada S. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther 2003, 8:207-219. 10.1016/S1525-0016(03)00170-9, 12907143.
172. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002, 4:70-76. 138723, 11879567, 10.1186/bcr426.
173. Mei Y, Xie C, Xie W, Wu Z, Wu M. Siah-1 S, a novel splice variant of Siah-1 (seven in absentia homolog), counteracts Siah-1-mediated downregulation of beta-catenin. Oncogene 2007, 26:6319-6331. 10.1038/sj.onc.1210449, 17420721.
174. Iwai A, Marusawa H, Matsuzawa S, Fukushima T, Hijikata M, Reed JC, Shimotohno K, Chiba T. Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates beta-catenin activity in a p53-dependent manner. Oncogene 2004, 23:7593-7600. 10.1038/sj.onc.1208016, 15326481.
175. Ridgeway AG, McMenamin J, Leder P. P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells. Oncogene 2006, 25:3518-3527. 10.1038/sj.onc.1209391, 16434961.
176. Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, Camp RL, Rimm DL. β-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 2004, 100:2084-2092. 10.1002/cncr.20232, 15139049.
177. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004, 28:1506-1512. 10.1097/01.pas.0000138183.97366.fd, 15489655.
178. Moser AR, Mattes EM, Dove WF, Lindstrom MJ, Haag JD, Gould MN. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci USA 1993, 90:8977-8981. 47484, 8415640, 10.1073/pnas.90.19.8977.
179. Gallagher RC, Hay T, Meniel V, Naughton C, Anderson TJ, Shibata H, Ito M, Clevers H, Noda T, Sansom OJ, Mason JO, Clarke AR. Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency. Oncogene 2002, 21:6446-6457. 10.1038/sj.onc.1205892, 12226748.